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Whether genetic, geographic, or acquired; a multitude of factors can bring about 
Herpesvirus 8 induced Kaposi’s Sarcoma, of which four subtypes have been identified: 
Classic, African endemic, AIDS-related, and iatrogenic Kaposi’s Sarcoma. A Case Study 
has been incorporated to illustrate the clinical manifestations of the latter type of 
Kaposi’s Sarcoma; a rather atypical occurrence in which the patient does not present with 
the characteristic purple, cutaneous lesions.  A mechanistic approach examines just how 
this tumor establishes latency in infection and how the Latency-Associated Nuclear 
Antigen (LANA) that Herpesvirus 8 encodes for, downregulates various regulatory 
proteins, such as tumor suppressor cells: p53, VHL, and the Retinoblastoma protein and 
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Introduction: An overview of the Disease 
Overview: 
Historically having been erroneously referred to as the “AIDS rash,” Classic Kaposi’s 
Sarcoma which is characterized by purple or red lesions was first discovered in 1872 by 
Moritz Kaposi, in older males of Jewish or Mediterranean descent. However, AIDS 
related or epidemic Kaposi’s’ Sarcoma is one of the four types of this cancer, later 
described in 1981 when an epidemic of Kaposi’s Sarcoma was observed in 95% of young 
heterosexual or bisexual males. Before then, around the 1950’s, an endemic took hold in 
Africa, particularly near the equatorial region affecting about 1 female in every 10-15 
males. Lastly, patients who were iatrogenically immunosuppressed as seen in transplant 
patients, for instance, were found to be at a significantly increased risk of developing 
Kaposi’s Sarcoma due to weakened immune responses from the drugs they are required 
to take to prevent graft or donor tissue rejection. Obviously, Kaposi’s Sarcoma can be 
transmitted sexually, vertically from mother to child, via blood transfusions, but the 
horizontal route by saliva is also a common mode of transmission (Pica F, Volpi A).  
Nevertheless, these four types of Kaposi’s Sarcoma are still distinguished by the 
dermal lesions that may first appear as a flat patch or plaque and progress into a raised 
nodule or tumor. Although the lesions are generally found on the skin, they can also 
develop in the gastrointestinal tract or respiratory tract and cause complications such as 
abdominal pain, bloody stool, and shortness of breath. According to clinical observations, 
Kaposi’s Sarcoma has been classified as a multifocal rather than metastatic neoplasm. 
Furthermore, blood vessels become leaky and high amounts of the iron-storage complex, 
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haemosiderin deposits into red blood cells. It wasn’t until 1994 when biopsies indicated 
that Herpesvirus 8 was the pathogen responsible for Kaposi’s Sarcoma and the term 
Kaposi’s Sarcoma-associated Herpesvirus was coined. What was discovered in these 
lesions and tumors was that KSHV attacked endothelial cells, particularly spindle cells; 
however more than just the integumentary system, KSHV targeted B lymphocytes as well 























 There is no universal system for staging Kaposi’s Sarcoma; however a proposed 
system is as follows: Macronodular is the first stage, characterized by small lesions 
usually confined to the lower extremities. Larger lesions such as plaques constitute the 
Stage II: Infiltrative Stage, while larger plaques and nodules define Stage III:  Florid 
Stage. Stage IV: Disseminated Stage extends beyond the lower extremities and is 
characterized by multiple large lesions (Roy, Sampurna, M.D.).  
Virology/Pathology: 
 Kaposi’s Sarcoma-associated Herpesvirus (KSHV) or also known as Herpesvirus 
8 belongs to the gammaherpesvirus family and targets B lymphocytes as well as 
endothelial cells for infection. KSVH is approximately 160 – 170 kilobase and has 
doubled stranded, linear DNA; however like all herpesviruses which can express latent or 
lytic infection, upon latent infection by KSHV, the viral genome exists as an episome 
(double stranded circular DNA). Typically the latent phase predominates but in 
immunocompromised patients in particular, latent cells can be reactivated into lytic 
replication which releases virions. The viral genome in lytic infection exists instead as a 
linear, double stranded DNA molecule (Ye, F., Lei, X., Gao, S.J.). A part of the coding 
region of Herpesvirus 8’s open reading frame (ORF) consists of at least 87 genes flanked 
by G-C rich terminal repeats that act as the origin of replication, thus the virus couples to 
the host’s cellular replication machinery. On each terminal repeat unit are two LANA 
(Latency-Associated Nuclear Antigen) binding sites: LBS1 and LBS2, the former has a 
greater affinity than the latter. (Verma, S.C., et al). Herpesvirus 8 tethers its genome to 
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the histones of the host chromosome and recruits the host cell’s replication machinery. 
The virus does so by to detecting cell signals and having regulatory sites on its promoter 
that bind host cell factors and thus triggers viral replication (Alka, P., Lu, M., Lukac, D., 
Zeichner, S).  
A number of genes that are viral homologues with oncogenic properties have been 
discovered to be associated with Herpesvirus 8 such as type D-cyclin, kaposin, vFLIP, 
and LANA. Type-D Cyclin which is also called HHV-8-v-cyclin and encoded by ORF72 
(West, J.T., Wood, C.),  is associated specifically with cyclin-dependent kinase 6 (Cdk6) 
which plays a role in control of the cell cycle checkpoints as well as in regulating tumor 
suppressor protein Retinoblastoma (Rb). Three types of kaposin, encoded by ORF12 
(Wen, K.W., Damania, B.) exist: A, B, and C and it has been shown in transfected Rat 
cells that Kaposin A has oncogenic potential in that it induces aggregation of 
lymphocytes (Zuckerman, A.J.) which explains why Kaposi’s Sarcoma is classified as a 
lymphoma. Cell proliferation is further progressed by vFLIP (viral FLICE-like inhibitory 
proteins) which inhibits apoptosis and as a result contributes to tumor survival 
(Zuckerman, A.J.). The key gene product of interest is LANA-1: latency-associated 
nuclear antigen, encoded by ORF73, which plays multifunctional roles to maintain the 
epsiome and bind the viral genome to the host chromosome as mentioned earlier (Verma, 
S.C, et al.). In order to maintain latency, LANA represses the transcriptional activity of a 
gene which activates the lytic phase involving viral replication and release of virions: 
RTA which stands for Replication and Transcription Activator, encoded by ORF50 
(Mesri, E.A., Cesarman, E., Boshoff, C). Despite its crucial role during latency, LANA 
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interferes with many regulatory proteins; in particular, tumor suppressors, of which will 
be the main focus of this paper.  
LANA targets proteins for degradation via ubiquitylation, such as the well known 
tumor suppressor proteins: p53, von- Hippel Lindau, and Retinoblastoma and thus in turn 
promotes tumorigenesis. p53 responds to cellular stresses by regulating apoptosis, 
controlling the cell cycle, sensing DNA damage, amongst other critical functions. 
Similarly, von Hippel-Lindau (VHL) regulates cell division and other genes but more 
importantly, the protein plays a role in sensing of oxygen levels. Its main function is to 
target the hypoxia-inducible transcription factor (HIF-1α) for degradation as HIF-1α 
promotes angiogenesis. Via direct and indirect mechanisms, which will be addressed in 
the second chapter, LANA also affects tumor suppressor protein Rb. Therefore, when 
LANA interferes with the functions of these tumor suppressors, viral proliferation 
persists.  
As for lytic infection by KSHV, which is reactivated by activation of Replication 
and Transcription Activator (RTA), gene expression in the host is repressed as a result of 
accelerated mRNA turnover mediated by viral SOX protein expression, which is involved 
in processing and packaging the genome of the herpesvirus. The SOX (shut off and 
exonuclease) protein degrades mRNA by reducing the half life of the mRNAs targeted 
and thereby activates host transcription of angiogenic or oncogenic factors. In summary, 
infection by KSHV of human endothelial cells leads to genetic instability, which is a 
hallmark of cancer in humans, causing aberrant formation of the spindle cell, 
chromosomal misalignment, duplication of centrosomes, and multinucleation (Si, H., 




 Often times Kaposi’s Sarcoma patients can be asymptomatic; however as 
mentioned earlier, one of the most apparent manifestations of Kaposi’s Sarcoma is the 
distinct red or purple lesions. Consequently, diagnosis of the cancer is confirmed via a 
biopsy of dermal lesions and to check for the more life-threatening lesions that may be in 
the lungs or gastrointestinal tract, a chest x-ray or bronchoscopy and a gastrointestinal 
endoscopy is performed. A CT (computerized tomography) scan can also be used to 
detect Kaposi Sarcoma in the lymphatic system. Since it is unlike other cancers and the 
type of Kaposi’s Sarcoma is a factor for consideration, staging the disease is taken by a 
case by case approach and stratification follows the system developed by the AIDS 
Clinical Trial Group which classifies risk by tumor, immune status, and systemic illness 
as summarized in table 1 below. The reason CD4 cell count is considered, is because 
LANA downregulates the Major Histocompatibility Complex II (MHC II), which 












Table 1: Diagnostic Scheme for Evaluating Kaposi’s Sarcoma 
 Shows the general diagnostic guide by which Kaposi’s Sarcoma is evaluated according 
to whether the risk is high or low depending on three main factors (Oncolink.org).  
 
 
Good Risk Low Risk 
Tumor Confined to skin and/or lymph nodes  
- Minimal oral disease (non-nodular KS confined to 
palate) 
-Tumor-associated edema or ulceration 





CD4 cell count >200/µL CD4 cell count <200/µL 
Systemic 
Illness 
-No history of opportunistic infections or thrush 
-No "B" symptoms- unexplained fever, night sweats, 
<10 percent involuntary weight loss, or diarrhea 
persisting more than two weeks.  
-Karnofsky performance status >70 (independent and 
functional without assistance) 
- History of OI or thrush 
- "B" symptoms present 
- Karnofsky performance status <70 
Other HIV-related illness (e.g., 
neurologic disease, lymphoma) 
 
Treatment:  
 Currently, there is no cure for Herpesvirus 8; thus the objective for treating 
Kaposi’s Sarcoma is to build immunity and induce regression. For patients diagnosed 
with AIDS-related Kaposi’s Sarcoma, HAART, which stands for highly active 
antiretroviral therapy has been implemented as a means of improving immunity in 
immunosuppressed patients via a mix of drugs, popularly referred to as the “AIDS 
cocktail.” The cocktail includes three major of classes of drugs aimed at reducing the 
virus: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and integrase inhibitors 
(Stuart, A). These inhibitors suppress the enzymes which are necessary for the 
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herpesvirus to produce more progeny. Inhibiting HIV-1 cofactors that promote tumor 
growth and reducing cytokine and pro-angiogenic production are some possible 
mechanisms of HAART that have been proposed to lead to regression of Kaposi’s 
Sarcoma. Radiation therapy, Intralesional Chemotherapy are other rational treatments, as 
well as the use of topical retinoids for the lesions. Potential drugs that target vascular 
endothelial growth factor (VEGF), vFLIP, and other factors that cause Kaposi’s Sarcoma 
are also being investigated, in which the biological effects include inhibiting 
angiogenesis, inflammation, and proliferation of spindle cells. Another potential therapy 
for treating Kaposi’s Sarcoma, particularly tumors is using Nutlin-3 which is a small 
imidazoline analog that disrupts the interaction between murine double minute (mdm2) 
















Latency-Associated Nuclear Antigen (LANA) of Kaposi’s Sarcoma Herpesvirus 
(KSHV) inhibits tumor suppressor proteins: p53, VHL, and Retinoblastoma and thus 
promotes oncogenesis. 
 
Human Herpesvirus 8 or Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) is unlike 
other viruses in that it not only pirates host genes but encodes many cellular homologues, 
one of which has been expressed in a significant majority of Kaposi’s Sarcoma 
malignancies: Latency-associated nuclear antigen (LANA). LANA is a protein encoded 
by open reading frame 73 on the viral genome and serves a crucial role in maintaining the 
episome during latency in infected host cells. In a lytic infection, the viral genome 
persists in a linear form. In order to maintain latency, LANA is capable of affecting many 
regulatory pathways such as apoptosis, cell cycle control, and transcription. 
 
The Structure of LANA 
 Three major domains (as shown in Figure 1 below) make up LANA’s amino acid 
sequence: a 337-amino acid N-terminal domain, 240-amino acid C terminal domain, and 
a 585 amino acid central domain comprised primarily of repeats of the amino acids: 
glutamic acid, aspartic acid, and glutamine (Verma, S.C., Lan, K., Robertson, E.). Both 
the N-terminal and the C-terminal contain a nuclear localization signal (NLS). The N-
terminal domain is rich in proline residues and is where LANA tethers to the histones of 
the host chromosome during mitosis, particularly to H2A and H2B while the C-terminal 
domain consists of a leucine zipper motif which is important in interactions with cellular 
proteins such as p53 (Hu, J., Garber, A.C., Renne, R.). It is these functionalities of the 
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LANA domains that help recruit the host replication machinery so that viral DNA can be 
replicated.  
 
Figure 1: Domains of LANA 
  
 
In addition to contributing to the proliferation of Herpesvirus 8, LANA supports 
viral persistence and tumorogenesis by interfering with tumor suppressor proteins. In 
inhibiting the p53 pathway which serves an anticancer function in regulating cell 
proliferation, LANA binds p53 to its C terminus, which plays a role in maintaining 
genetic stability, regulating programmed cell death and arresting the cell cycle at the G1 
checkpoint to prevent excessive cell growth in response to stressors such as hypoxia, 
oncogenes, and DNA damage. According to an experiment conducted by Si Huaxin and 
Erie Robertson, the LANA transfected cell lines that they generated not only 
demonstrated an increase in cells entering S phase, thereby amplifying cell proliferation, 
the human B cells (from the BJAB cell line) expressing LANA indicated chromosomal 
instability which was marked by multinucleation and abnormal centrosomes, as well as 
micronuclei. More than 15% of the cells expressing LANA had three or more 
centrosomes per cell compared to the less than 2% in the controls without LANA 





Inhibition of the p53 pathway by LANA 
The mechanism by which LANA inhibits p53 function involves recruiting the 
EC5S Ubiquitin Complex, (illustrated in Figure 2) which tags the tumor suppressor 
protein for degradation via the ubiquitylation process. The Ubiquitin Complex 
accomplishes the tagging process with the help of an E3 ligase encoded by the SOCS-
box-motif (Suppressors of Cytokine Signaling box) of LANA and its interaction with E1 
and E2 to transfer the ubiquitin to the protein targeted for degradation. E1 is an ubiquitin-
activating enzyme which transfers ubiquitin to E2, a conjugating enzyme. In other words, 
LANA interferes by mimicking a molecule that adapts specifically to the E3 complex 
The E2-SOCS-box protein associates with an Elongin BC Complex through binding of a 
Cul5/Rbx1 hemagglutinin module which stabilizes LANA. It has been shown that 
Elongin C of the Elongin BC Complex interacts with the amino-terminal of LANA (Cai, 
Q., et al.). Together, these components comprise of the EC5S Ubiquitin Complex that 
marks p53 and VHL for degradation. Phosphorylation of p53 by various kinases can lead 
to interaction of the tumor suppressor to either activators of transcription or negative 
regulators such as the human double minute 2 protein (hdm2) through its E3 
ubiquitination ligase activity that targets p53 for degradation (Chen, W. et al.). In mice, 
the formation of tumors were observed in the presence of mdm2 (murine double minute 
2) expression which is homologous to hdm2 therefore indicating that hdm2/mdm2 is an 
oncogene. Furthermore when Chen et al., immunoprecipitated hdm2, LANA was 
detected, thus suggesting that LANA also interferes with this p53 negative regulator. It 
has been suggested that hdm2 either interacts with LANA directly or indirectly by 
changing the conformation of p53 so that it has affinity in binding LANA. It is through 
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the release of hdm2, along with other posttranslational modifications, that activate p53 
when DNA damage is detected. As mentioned in the treatment section of Chapter 1, the 
Nutlin-3 molecule has cytotoxic effects which interferes with the interaction between p53 
and mdm2, leading to apoptosis in KSHV-infected cells. Nutlin disrupts this interaction 
by acting as a competitive inhibitor (Sarek, G., et al.).  
Another mechanism by which LANA downregulates p53 is in upregulating the 
abnormal expression of Aurora A kinase which has been known to regulate tumorigenesis 
and induce chromosomal instability. In fact, overexpression of Aurora A is actually quite 
common in many tumor type cancers in humans, so unsurprisingly increased mRNA 
transcript of Aurora A was found in KSHV positive tissue but not in KSHV negative 
tissue in the experiment done by Cai, et al. In other words, this kinase which is a 
checkpoint protein in mitosis associated with the centrosome, enhances the affinity of 
p53 for binding to LANA and destabilizes p53 by upregulating an oncogene (Cai, Q., et 
al). To confirm that LANA does affect Aurora A and therefore p53, Cai, et al. 
knockdowned LANA and as a result they observed a reduction in Aurora A transcripts. 
The mechanism behind this reveals that LANA targets one of the three cis elements 
comprising the promoter of Aurora A: transcription factor Sp1. Furthermore, Aurora A 
enhances the first mechanism discussed: ubiquitylation of p53 by augmenting the tagging 
function of LANA’s SOC-motif. Phosphorylation at Serine residues 215 and 315 also 





Downregulation of VHL by LANA 
As with p53, the von-Hippel-Lindau (VHL) tumor suppressor which regulates 
oxygen concentration and gene expression (refer to Figure 2), is degraded by the 
ubiquitin protein in the same manner described above for the deregulation of p53. 
Regulation by VHL is necessary because under conditions of hypoxia (low oxygen), 
hypoxia-inducible factors (HIFs), in particular HIF-1α activates a number of genes that 
promote angiogenesis, which feed tumors the necessary nutrients it needs to flourish. As 
a result of deregulation of von-Hippel-Lindau by LANA, HIF-1α is stabilized and the 
hypoxia pathway therefore prevails, contributing to the development of tumors as 
paracrine angiogenic and inflammatory factors such as VEGF (Vascular Endothelial 
Growth Factor) are secreted (Mesri, E.A., Cesarman, E., Boshoff, C.). 
Figure 2: VHL Regulatory Activity 
Shows VHL regulation of oxygen levels and its activity. Under conditions of Normoxia, 
VHL tags HIF-1α for degradation via ubiquitylation; however in conditions of hypoxia, 
HIF-1α activates factors that increase the levels of oxygen. *It should be noted, that Cul2 
should actually be Cul 5 as confirmed in a study done by Qi-Liang Cai, et al. 








LANA deregulates the Retinoblastoma protein 
 Retinoblastoma (pRb) is another tumor suppressor protein that belongs to the 
“pocket binding protein” family and is responsible for regulation of the cell cycle at the 
G1 checkpoint to assure that damaged DNA does not proceed into the S phase for 
replication.  pRb interacts with the E2F family of transcription factors, triggering 
suppression of cell growth (Verma, S.C., Lan, K., Robertson, E.). When pRb is in its 
inactive state which is induced by Cyclin Dependent Kinases (Cdks) phosphorylation 
(hyperphosphorylation), cell cycle progression occurs while hypophosphorylation turns 
the protein on by causing the E2F factors to dissociate so that progression into the S 
phase can be inhibited. Typically D type cyclins are associated with Cdk 6 which initiates 
a cascade that phosphorylates protein Retinoblastoma. However as mentioned in Chapter 
1, the KSHV encoded homolog v-cyclin, which acts like D-type cyclins, have been 
known to hyperphosphorylate pRb, thus deregulating pRb and mediating cell 
proliferation, providing an explanation for the progression of Kaposi’s Sarcoma into the 
nodular phase.  Biopsies of Kaposi’s Sarcoma lesions expressing v-cyclin transcripts 
further confirm the role of v-cyclin in promoting oncogenesis (Kennedy, M.M, et al.). 
Just as with p53, VHL, and many other proteins, LANA also binds to pRb, competing 
with the E2F factors as shown in Figure 3  (Verma, S.C., Lan, K., Robertson, E.). Via an 
indirect mechanism, LANA also stimulates cells in the resting G0 phase to enter the cell 
cycle by stabilizing β-catenin through binding to the Glycogen Synthase Kinase-3-beta 
(GSK-3-beta). The gene that codes for the protein, β-catenin can serve as an oncogene 
and overexpression of this protein has been found in Kaposi’s Sarcoma tissue (Fujimuro 
M., et al).  
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Figure 3: LANA interference with Retinoblastoma protein 
 LANA competes with the E2F transcription factors in binding to the Retinoblastoma 









 As the mechanisms addressed have shown, the Latency-Associated Nuclear 
Antigen of Herpesvirus 8 has a broad binding affinity for many regulatory proteins in our 
bodies. Of particular interest, is the fact, that deregulation of such proteins as the tumor 
suppressors: p53, VHL, and Retinoblastoma promote their proliferation and persistence 
in latently-infected hosts by upregulating factors favorable for oncogenesis. Much 
research is still being conducted on this newest member of the Herpesvirus Family, with 
particular emphasis on its encoded LANA and its interaction. Future directions for 
research hold potential for possibly finding an effective treatment for Kaposi’s Sarcoma 




Clinical Case Study 
ID and Chief Complaint:  
Elijah is a 30 year old African American male who came in to the office, complaining of 
chest pain and shortness of breath (dypsnea).        
 
History of Present Illness:          
 Elijah came in for a doctor’s visit, presenting with chest pain which he has been 
experiencing for about a month now and which has progressively gotten worse over this 
time. The chest pain started off as intermittent, but has now become more frequent and 
the pain much more intolerable. On a scale of 10, Elijah describes the chest pain as a 7, 
stating that it feels as if bricks have been placed on his chest, making it difficult for him 
to expand his cavity when he breathes. Elijah reports that the chest pain usually lasts for a 
few minutes and does not radiate to any other part of the body, such as the neck or arms. 
He has not taken any medication to alleviate his chest pain.  
With his chest pain, he has also been experiencing shortness of breath over the 
past 3 weeks, where his inhalations are very shallow and as mentioned earlier, there is a 
feeling of tightness in his chest. For Elijah, who is a very active individual, shortness of 
breath is very uncommon; however recently it has become a recurring problem for him. 
He has also noted that the shortness of breath not only occurs during light exercise but is 
more prominent following the onset of his chest pain and he mentions that his symptoms 
have prohibited him from doing the activities he enjoys on a daily basis. Although Elijah 
experiences chest pain, on average, once or twice a day, his shortness of breath occurs 
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more often throughout the day. There have also been a two or three episodes where he 
has woken up from his sleep due to shortness of breath. 
Elijah is otherwise a healthy being and has not been in contact with any sick 
individuals. His immunizations are up to date and he recently received his influenza 
vaccination which he developed a sore throat and runny nose in response to the shot, but 
these symptoms lasted only a few days. 
Past Medical History:    
• End stage renal disease due to rhabdomyolysis  
• Surgeries  
-Kidney Transplant in January 2010 
-ACL reconstruction 2009  
• Medications 
-Cyclosporine (by mouth) for renal transplant  
-Melatonin  
• Allergies 
-No known drug allergies 
 
Family History: 
• Sister is lactose intolerant 
• Grandfather is dyslipidemic (high blood cholesterol) 






• -Marital status: Engaged and lives with fiancé 
• -Sexually active; use of condoms 
• -No children, but plan on having one in the near future  
• -Occupation: business executive and fiancé is an elementary school teacher 
• -Tobacco: denies use 
• -Illicit drugs: denies use  
• Alcohol: occasional beer or two a month 
• Caffeine: a cup a day in the morning  
• Exercise: active-enjoys working out, rock climbing, racquetball, and 
snowboarding 
• Diet: balanced-meat, vegetables, fruits, grains 
• Has not traveled anywhere in the last few years  
 
Review of Systems: 
• Constitutional: fevers at night starting two days ago, no chills, nor any weight loss 
or gain or loss of appetite, some fatigue. 
• HEENT: 
◊ head: no dizziness; however occasional headaches (side effect of 
Cyclosporine), no neck pain 
◊ ears: no loss of hearing or earache/ear infection  
◊ eyes: no changes in visual acuity 
◊ nose: no runny nose, sinuses, or congestion, no tinnitus (ringing) 
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◊ throat: no dysphagia (difficulty swallowing), no toothache or mouth sores, 
tonsils present 
• Cardiovascular: chest pain, no tachycardia or brachycardia, intolerance of 
exercise,  
• Respiratory: shortness of breath; Paroxysmal Nocturnal Dypsnea (PND-sudden 
shortness of breath when sleeping- 2 to 3 occurrences), occasional cough (side 
effect of Cyclosporine), hemoptysis (began coughing up blood the last two days), 
no wheezing  
• GI: no abdominal pain, no nausea, vomiting, or indigestion, no abdominal pain, 
stool is normal; no constipation or diarrhea, no heartburn or acid reflux. No eating 
disorder 
• GU (genitor-urinary): kidney transplant, no rejection of transplant detected, no 
nocturia or polyuria, no incontinence (unintentional urine loss), no difficulties 
urinating, no erectile dysfunction or testicular pain, no history of STDs 
• Integumentary: no bruises, rashes, irregular growths, dermal lesions, or skin 
irritation, no jaundice, redness, or any skin discoloration, no hair loss, nails appear 
healthy 
• MS (musculoskeletal): no hip, joint, shoulder, or back pain, some swelling in legs, 
and feeling of muscle weakness, ACL injury, no stiffness or restrained 
movements  




• Mental: no depression, confusion, anxiety, or any other mental health disorder. 
No alcohol or substance abuse. No memory loss 
Physical Exam 
• Vitals: 
◊ Temperature: 99˚F (rechecked: 99.3˚F) 
◊ Blood pressure: 84/50 mmHg (rechecked: 82/50) 
◊ Pulse: 88 beats per minute  
◊ Respirations: 20 breaths per minute 
◊ Pulse Oximetry: 86% Saturation  
◊ Height: 5’ 8” 
◊ Weight: 148 lbs 
◊ BMI: 22.5 
• HEENT: 
◊ NCAT (Normocephalic atraumatic): size and shape of head appears 
normal, no tenderness upon palpitation 
◊ PERRL: (pupils equally round and reactive to light), red eye reflex intact, 
no conjunctivitis  
◊ EOMI: (extraocular muscles intact), tympanic membrane clear, no fluid or 
significant earwax, no inflammation  
◊ clear discharge from nose, moist mucous membranes, no sinuses 
◊ no JVD (jugular venous distention) noted, slight tenderness and swelling 
of lymph nodes in neck region 
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• Cardiovascular: heart rate within normal range, no tachycardia or brachycardia, 
murmurs/bruits, gallops, or irregular palpitations 
• Respiratory: dypsnea, hypoxemia  
◊ Observation: use of some accessory muscles, no difficulty speaking, 
difficulty breathing especially during inhalation, slight 
inclination/slouching forward upon inhalation, no barrel chest, no cyanosis 
(turning blue) or pursed lips  
◊ Palpation: trachea is medial, Fremitus (vocal vibratory sensation) is 
asymmetric-decreased, chest pain   
◊ Percussion: dull resonance 
◊ Auscultation: exhalations are louder than inhalations, no crackles, rales 
(scratchy sounds), ronchi (gurgling), moderate wheezing  
• Abdomen:  
◊ Observation: not obese, symmetrical, no rashes or visible abnormalities , 
evidence of renal transplant surgery  
◊ Palpation: no hernia or protuberances, some tenderness in both upper left 
and right quadrants with deep palpitations  
◊ Percussion: liver span approximates 10cm with dull resonance, tympanitic 
stomach resonance, detection of fluid was negative   
◊ Auscultation: no irregular bowel movement sounds, no bruits (sound of 
turbulent arterial flow)  
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• Extremities: some edema in lower extremities, particularly near groin region, 
ACL reconstruction scar, no clubbing either, 2 second capillary refill in toes.  
• GI: no enlarged organs or distentions detected 
• GU: no tenderness, rashes, or growths 
• Integumentary: normal skin coloration, health nailbeds, some swelling noted in 
leg; otherwise no lesions or rashes  
• MS: normal flexion/extension and abduction/adduction movements, no muscular 
atrophy; however 3/5 muscle strength, all ranges of motion (active and passive) 
are normal and painless, no effusion of joints noted, McMurray’s Test for torn 
meniscus-negative, shoulder rotations are fine  
• Neurological: intact sensations to pain and touch, patellar and all other reflexes 
are normal, normal proprioception, gait, and responses to cranial nerve 
assessments, no numbness, dizziness, or loss of consciousness 
• Mental: no mood swings, anxiety, or depression  
 
Labs and Radiology: 
• CBC: results suggest anemia     Reference Ranges 
-WBC count: 3,500/μL     (4,500-11,000 cells/μl) 
-RBC count: 3.9million/μL     (3.8-5.8million cells/μ/l) 
-CD4+ T-cell count: 300 cells/mm3    (440-1600 cells/mm3)  
-Hemoglobin: 12.8 g/dl     (13.2-17.3g/dl) 
-Hematocrit: 38%      (39-49%) 
-MCH: 32.8pg       (27-34pg) 
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-MCV: 97 fL      ( 80-99fL) 
- MCHC: 33.7 g/dl     (32-37g/dl)   
-Platelet count: 100,000     (150,000-400,000 cells/μl) 
-Total lymphocytes: 30%      (normal: 33%) 
-Neutrophils: 51%     (54-80%) 
-Eosinophils: 3%      (0-5%) 
-Basophils: 1%       (0-2%) 
-Monocytes: 15%     (0-10%) 
• Iron panel  
-Total iron: 350 ng/ml      (60-170 ng/ml)   
-Ferritin: 310 ng/mL      (18-250 ng/ml) 
• Lipid panel 
-LDL cholesterol: 80 mg/dl   (62-130 mg/dl)   
-HDL cholesterol: 70 mg/dl    (35-135 mg/dl) 
-triglycerides: 130 mg/dl     (0-200 mg/dl) 
• B.U.N: 24 mg/dL      (8-20 mg/dl) 
• Creatine: 1.6 mg/dL      (0.7-1.4 mg/dl) 
• Bilirubin (direct): 0.4 mg/dL     (0-0.3 mg/dl) 
• Alkaline phosphatase: 148 U/L    (20-125 U/L) 
• Serum potassium: 5.8 mEq/L     (3.5-5.5 mEq/L) 
• Serological exam 
-HIV: (-) 
-TB antibody: (-) 
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• Cardiac markers/enzymes 
-troponin: 0 ng/mL     (<0.1 ng/ml) 
-CPK: 85 Units/L     (38-174 units/L) 
-myoglobin: 75 ng/mL    (10-95 ng/ml) 
• EKG 
- tall tented T-waves were noted which is a possible indication of moderate 
hyperkalemia. The ventricular extrasystoles observed likely correspond to the 
shortness of brain and chest pain. P waves were absent and the QRS complex was 
rather broad.   
• Figure 4: Chest X-ray 
An X-ray of the patient’s chest showed a cloudy appearance, indicating mild 
pleural effusion. Ill-defined nodules and opacities ranging from 4-12mm in 














• Figure 5: CT scan  
Peribronchovascular septal thickening was noted in the CT scan of the patient’s 








• Bronchoscopy  
-Bright red lesions noted in lower portion of bronchi  
• Lung Biopsy 










• Thrombocytopenia  
Differential Diagnosis 
• Cardiac complications  
-Coronary heart disease  
-Congestive heart failure  
-myocardial infarction   





-acute pulmonary edema 
 -sarcoidosis of lungs  
• Other 
-Kaposi’s Sarcoma  
 
Assessment 
 Elijah’s primary symptoms of chest pain and shortness of breath suggested that 
whatever was ailing him must be pulmonary or associated with the cardiovascular 
system; therefore an EKG and x-ray were done. The wave pattern of his EKG with 
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extrasystoles reflected his chief complaint; however tented T waves were also observed, 
indicating that the patient had hyperkalemia. Lab results confirmed elevated levels of 
potassium. Despite an irregular EKG, angina was deemed an unlikely differential and 
therefore atherosclerosis/coronary heart disease were ruled out upon normal results 
obtained from a lipid panel. Because Elijah had some swelling in his lower extremities, 
anemia, and his chest X-ray showed pleural effusion, myocardial infarction and 
congestive heart failure had initially been considered a possible differential; however a 
test with cardiac markers: troponin and CPK indicated otherwise. 
 
  The pleural effusion noted in Elijah’s chest x-ray and septal thickening shown on 
a CT scan of his lungs pointed to many possible pulmonary related differentials but what 
led to the ultimate diagnosis was the decision to proceed with a biopsy of the ill-defined 
nodules found on the upper quadrants of both lungs from the bronchoscopy. Remarks 
from pathology of the samples included spindle cell proliferation and along with all the 
lab results thus far, the diagnosis was ascertained to be Kaposi’s Sarcoma.  
 
 Although typical cases of Kaposi’s Sarcoma present as defined bluish-purple skin 
lesions, Elijah was diagnosed with iatrogenic Kaposi’s Sarcoma. Looking back at his 
medical history, the fact that Elijah has been taking cyclosporine, as prescribed for his 
renal transplant, explains the elevated bilirubin and hyperkalemia as the 
immunosuppressant drug warns of these side effects. Such immunosuppressant drugs, 
and particularly, cyclosporine, increase the risk of transplant patients being diagnosed 
with Kaposi’s Sarcoma as it promotes excessive production of Vascular Endothelial 
Growth Factor (VEGF). The low numbers from the CBC count verified 
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immunosuppresion in the patient where the characteristic Kaposi’s Sarcoma nodules 
manifested on Elijah’s lungs which led to the chest pain and shortness of breath he was 
experiencing and development of these lesions eventually caused hemoptysis. 
 
Treatment Plan and Follow up 
 The immunosuppressant drug, Cyclosporine has been shown to increase the risk 
of transplant patients becoming susceptible to being diagnosed with Kaposi’s Sarcoma as 
it promotes excessive VEGF (vascular endothelial growth factor) production and cancer 
progression, rather than targeting Kaposi’s Sarcoma Associated Herpesvirus (KSHV or 
Herpesvirus 8) for apoptosis or the lytic cycle. Instead, an alternative 
immunosuppressant, Sirolimus not only provides the protection from graft rejection, but 
has been shown to be effective in the regression of Kaposi’s Sarcoma. Therefore, in 
treating Elijah, Cyclosporine was discontinued and Sirolimus was prescribed and a follow 
up appointment in three months has been set . By then, the lesions should disappear. 
Typically, Kaposi’s Sarcoma patients can undergo HAART (Highly Active Antiretroviral 
Therapy); however this treatment option better suits patients who have are HIV positive. 
The patient was advised against strenuous exercise and Ibuprofen, taken as needed, was 
suggested for temporary relief due to chest pain. In a 3 month follow up appointment, 
Kaposi’s Sarcoma should have regressed with reduction or disappearance of the lesions 
as well as the swelling.  
 
 Oftentimes, secondary cancers can develop succeeding the onset of Kaposi’s 
Sarcoma, one common disease is non-Hodgkin lymphoma and the prognosis assessed for 
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Elijah is that this is a concern as Kaposi’s Sarcoma had progressed fairly well in its stage. 
Although lesions did not manifest on his skin, their presence in the lungs particularly 
pose greater urgency as the other systems of the body can be severely affected by the 
respiratory complications associated. Furthermore, some swelling of lymph nodes was 
noted in Elijah, near the groin region; therefore future office visits will follow up with 
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